Merck (MRK) reported Q3 FY 2018 earnings of $1.19 per share (versus $1.11 in Q3 FY 2017), beating analysts' consensus estimate of $1.14.

The company's quarterly revenues amounted to $10.794 bln (+4.5% y/y), slightly missing analysts' consensus estimate of $10.896 bln.

The company also issued guidance for FY 2018, projecting EPS of $4.30-4.36 (compared to its prior guidance of $4.22-4.30 and analysts' consensus estimate of $4.29) and revenues of $42.1-42.7 bln (compared to its prior guidance of $42-42.8 bln and analysts' consensus estimate of $42.54 ).

MRK rose to $71.50 (+1.36%) in pre-market trading.